Leader in Biomolecular Solutions for Life Science

Human CD19 Monoclonal Antibody (N297Q)

Catalog No.: YR0502



Basic Information

Molecular Weight 150 kDa

Endotoxin <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay

Sterility 0.2 μm filtration

Aggregation <5% Determined by SECP

Purity >95% Determined by SDS-PAGE

Background

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical P K and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone Loncastuximab Biosimilar **Isotype** Human IgG1 kappa

Immunogen

RecommendedIsotype Control(s)

Recommended Dilution Buffer 1×PBS pH 7.3

Contact

6	400-999-6126
\times	cn.market@abclonal.com.cn
€	www.abclonal.com.cn

Product Information


Production Purified from cell culture supernatant in an animal-free facility


Purification Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Validation Data





Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD19 (Research Grade Loncastuximab(N297Q) Biosimilar) Monoclonal Antibody to CD19.The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection. Human CD19 SPR assay. Determined through SPR assay, the Human Anti-Human CD19 (Research Grade Loncastuximab (N297Q) Biosimilar) Monoclonal Antibody is Capable of binding to Human CD19 with an affinity constant of 1.288nM.